{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:21:04Z","timestamp":1791908464193,"version":"4.3.4"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T00:00:00Z","timestamp":1770076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T00:00:00Z","timestamp":1770249600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32370845"],"award-info":[{"award-number":["32370845"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82530005"],"award-info":[{"award-number":["82530005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82470214"],"award-info":[{"award-number":["82470214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012165","name":"Key Technologies Research and Development Program","doi-asserted-by":"publisher","award":["2022YFA1105003"],"award-info":[{"award-number":["2022YFA1105003"]}],"id":[{"id":"10.13039\/501100012165","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Exp Hematol Oncol"],"DOI":"10.1186\/s40164-026-00751-x","type":"journal-article","created":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T14:45:59Z","timestamp":1770129959000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Single-cell profiling reveals reprogrammed hierarchy and disrupted immune-stromal ecosystem in TP53-mutated AML"],"prefix":"10.1186","volume":"15","author":[{"given":"Guo","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyue","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongtao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengjiao","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyan","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueping","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menglin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanjia","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangmei","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sijian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guopan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengcheng","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifa","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,3]]},"reference":[{"issue":"7","key":"751_CR1","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/0092-8674(89)90045-7","volume":"57","author":"CA Finlay","year":"1989","unstructured":"Finlay CA, Hinds PW, Levine AJ. The p53 proto-oncogene can act as a suppressor of transformation. Cell. 1989;57(7):1083\u201393.","journal-title":"Cell"},{"issue":"4","key":"751_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41580-019-0110-x","volume":"20","author":"A Hafner","year":"2019","unstructured":"Hafner A, Bulyk ML, Jambhekar A, Lahav G. The multiple mechanisms that regulate p53 activity and cell fate. Nat Rev Mol Cell Biol. 2019;20(4):199\u2013210.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"751_CR3","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41392-023-01347-1","volume":"8","author":"H Wang","year":"2023","unstructured":"Wang H, Guo M, Wei H, Chen Y. Targeting p53 pathways: mechanisms, structures, and advances in therapy. Signal Transduct Target Ther. 2023;8(1):92.","journal-title":"Signal Transduct Target Ther"},{"issue":"15","key":"751_CR4","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1182\/blood.2021014472","volume":"139","author":"T Grob","year":"2022","unstructured":"Grob T, Al Hinai ASA, Sanders MA, Kavelaars FG, Rijken M, Gradowska PL, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139(15):2347\u201354.","journal-title":"Blood"},{"issue":"1","key":"751_CR5","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/s41408-025-01290-0","volume":"15","author":"MV Shah","year":"2025","unstructured":"Shah MV, Hung K, Baranwal A, Wechalekar G, Al-Kali A, Toop CR, et al. Validation of the 5th edition of the world health organization and international consensus classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort. Blood Cancer J. 2025;15(1):88.","journal-title":"Blood Cancer J"},{"issue":"1","key":"751_CR6","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41408-024-01186-5","volume":"14","author":"M Shahzad","year":"2024","unstructured":"Shahzad M, Amin MK, Daver NG, Shah MV, Hiwase D, Arber DA, et al. What have we learned about TP53-mutated acute myeloid leukemia? Blood Cancer J. 2024;14(1):202.","journal-title":"Blood Cancer J"},{"issue":"21","key":"751_CR7","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1182\/blood.2024025409","volume":"144","author":"H D\u00f6hner","year":"2024","unstructured":"D\u00f6hner H, DiNardo CD, Appelbaum FR, Craddock C, Dombret H, Ebert BL, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169\u201373.","journal-title":"Blood"},{"issue":"7","key":"751_CR8","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","volume":"36","author":"JD Khoury","year":"2022","unstructured":"Khoury JD, Solary E, Abla O, Akkari Y, Alaggio R, Apperley JF, et al. The 5th edition of the world health organization classification of haematolymphoid tumours: myeloid and Histiocytic\/Dendritic neoplasms. Leukemia. 2022;36(7):1703\u201319.","journal-title":"Leukemia"},{"issue":"1","key":"751_CR9","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13045-023-01424-6","volume":"16","author":"RS Bhansali","year":"2023","unstructured":"Bhansali RS, Pratz KW, Lai C. Recent advances in targeted therapies in acute myeloid leukemia. J Hematol Oncol. 2023;16(1):29.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"751_CR10","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13045-023-01417-5","volume":"16","author":"NG Daver","year":"2023","unstructured":"Daver NG, Iqbal S, Renard C, Chan RJ, Hasegawa K, Hu H, et al. Treatment outcomes for newly diagnosed, treatment-na\u00efve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis. J Hematol Oncol. 2023;16(1):19.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"751_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s13045-023-01437-1","volume":"16","author":"H Jin","year":"2023","unstructured":"Jin H, Zhang Y, Yu S, Du X, Xu N, Shao R, et al. Venetoclax combined with Azacitidine and Homoharringtonine in Relapsed\/Refractory AML: A Multicenter, phase 2 trial. J Hematol Oncol. 2023;16(1):42.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"751_CR12","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1158\/1078-0432.CCR-24-1332","volume":"31","author":"G Yu","year":"2025","unstructured":"Yu G, Zhang Y, Yu S, Yin Z, Weng G, Xu N, et al. Homoharringtonine added to venetoclax and Azacitidine improves outcome and mitigates genetic impact in Relapsed\/Refractory AML: A multicenter cohort study. Clin Cancer Res. 2025;31(1):87\u201397.","journal-title":"Clin Cancer Res"},{"issue":"53","key":"751_CR13","doi-asserted-by":"publisher","first-page":"7644","DOI":"10.1038\/sj.onc.1203015","volume":"18","author":"ND Lakin","year":"1999","unstructured":"Lakin ND, Jackson SP. Regulation of p53 in response to DNA damage. Oncogene. 1999;18(53):7644\u201355.","journal-title":"Oncogene"},{"issue":"11","key":"751_CR14","doi-asserted-by":"publisher","first-page":"2619","DOI":"10.1038\/s41375-019-0550-5","volume":"33","author":"A Cazzola","year":"2019","unstructured":"Cazzola A, Schlegel C, Jansen I, Bochtler T, Jauch A, Kr\u00e4mer A. TP53 deficiency permits chromosome abnormalities and karyotype heterogeneity in acute myeloid leukemia. Leukemia. 2019;33(11):2619\u201327.","journal-title":"Leukemia"},{"issue":"7","key":"751_CR15","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1158\/2159-8290.CD-19-0125","volume":"9","author":"T Nechiporuk","year":"2019","unstructured":"Nechiporuk T, Kurtz SE, Nikolova O, Liu T, Jones CL, D\u2019Alessandro A, et al. The TP53 apoptotic network is a primary mediator of resistance to BCL2 Inhibition in AML cells. Cancer Discov. 2019;9(7):910\u201325.","journal-title":"Cancer Discov"},{"issue":"9","key":"751_CR16","doi-asserted-by":"publisher","first-page":"2087","DOI":"10.1038\/s41375-025-02668-6","volume":"39","author":"SJ Skuli","year":"2025","unstructured":"Skuli SJ, Bakayoko Ai, Kruidenier M, Manning B, Pammer P, Salimov A, et al. Chemoresistance of TP53 mutant acute myeloid leukemia requires the mevalonate byproduct, geranylgeranyl pyrophosphate, for induction of an adaptive stress response. Leukemia. 2025;39(9):2087\u201398.","journal-title":"Leukemia"},{"issue":"103","key":"751_CR17","doi-asserted-by":"publisher","first-page":"eadr0782","DOI":"10.1126\/sciimmunol.adr0782","volume":"10","author":"K Maurer","year":"2025","unstructured":"Maurer K, Park CY, Mani S, Borji M, Raths F, Gouin KH 3, et al. Coordinated immune networks in leukemia bone marrow microenvironments distinguish response to cellular therapy. Sci Immunol. 2025;10(103):eadr0782.","journal-title":"Sci Immunol"},{"issue":"1","key":"751_CR18","first-page":"27","volume":"4","author":"A Lasry","year":"2023","unstructured":"Lasry A, Nadorp B, Fornerod M, Nicolet D, Wu H, Walker CJ, et al. An inflammatory state remodels the immune microenvironment and improves risk stratification in acute myeloid leukemia. Nat Cancer. 2023;4(1):27\u201342.","journal-title":"Nat Cancer"},{"issue":"1","key":"751_CR19","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13045-024-01634-6","volume":"18","author":"A Glaviano","year":"2025","unstructured":"Glaviano A, Lau HS, Carter LM, Lee EHC, Lam HY, Okina E, et al. Harnessing the tumor microenvironment: targeted cancer therapies through modulation of epithelial-mesenchymal transition. J Hematol Oncol. 2025;18(1):6.","journal-title":"J Hematol Oncol"},{"issue":"24","key":"751_CR20","doi-asserted-by":"publisher","first-page":"2812","DOI":"10.1182\/blood.2020006158","volume":"136","author":"DA Sallman","year":"2020","unstructured":"Sallman DA, McLemore AF, Aldrich AL, Komrokji RS, McGraw KL, Dhawan A, et al. TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype. Blood. 2020;136(24):2812\u201323.","journal-title":"Blood"},{"issue":"5","key":"751_CR21","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.cmet.2020.09.001","volume":"32","author":"D Forte","year":"2020","unstructured":"Forte D, Garc\u00eda-Fern\u00e1ndez M, S\u00e1nchez-Aguilera A, Stavropoulou V, Fielding C, Mart\u00edn-P\u00e9rez D, et al. Bone marrow mesenchymal stem cells support acute myeloid leukemia bioenergetics and enhance antioxidant defense and escape from chemotherapy. Cell Metab. 2020;32(5):829\u2013e439.","journal-title":"Cell Metab"},{"issue":"5909","key":"751_CR22","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1126\/science.1164390","volume":"322","author":"A Colmone","year":"2008","unstructured":"Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E, Sipkins DA. Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science. 2008;322(5909):1861\u20135.","journal-title":"Science"},{"issue":"12","key":"751_CR23","doi-asserted-by":"publisher","first-page":"3120","DOI":"10.1016\/j.cell.2024.04.013","volume":"187","author":"S Bandyopadhyay","year":"2024","unstructured":"Bandyopadhyay S, Duffy MP, Ahn KJ, Sussman JH, Pang M, Smith D, et al. Mapping the cellular biogeography of human bone marrow niches using single-cell transcriptomics and proteomic imaging. Cell. 2024;187(12):3120\u2013e4029.","journal-title":"Cell"},{"issue":"10","key":"751_CR24","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1038\/s41580-023-00615-w","volume":"24","author":"A Baysoy","year":"2023","unstructured":"Baysoy A, Bai Z, Satija R, Fan R. The technological landscape and applications of single-cell multi-omics. Nat Rev Mol Cell Biol. 2023;24(10):695\u2013713.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"1","key":"751_CR25","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s13045-025-01722-1","volume":"18","author":"X Cheng","year":"2025","unstructured":"Cheng X, Peng T, Chu T, Yang Y, Liu J, Gao Q, et al. Application of single-cell and Spatial omics in Deciphering cellular hallmarks of cancer drug response and resistance. J Hematol Oncol. 2025;18(1):70.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"751_CR26","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1038\/s41588-024-01999-x","volume":"56","author":"AM Lepp\u00e4","year":"2024","unstructured":"Lepp\u00e4 AM, Grimes K, Jeong H, Huang FY, Andrades A, Waclawiczek A, et al. Single-cell multiomics analysis reveals dynamic clonal evolution and targetable phenotypes in acute myeloid leukemia with complex karyotype. Nat Genet. 2024;56(12):2790\u2013803.","journal-title":"Nat Genet"},{"issue":"9","key":"751_CR27","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1038\/s41588-023-01480-1","volume":"55","author":"A Rodriguez-Meira","year":"2023","unstructured":"Rodriguez-Meira A, Norfo R, Wen S, Ch\u00e9deville AL, Rahman H, O\u2019Sullivan J, et al. Single-cell multi-omics identifies chronic inflammation as a driver of TP53-mutant leukemic evolution. Nat Genet. 2023;55(9):1531\u201341.","journal-title":"Nat Genet"},{"issue":"9","key":"751_CR28","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/S1470-2045(20)30455-1","volume":"21","author":"L Xuan","year":"2020","unstructured":"Xuan L, Wang Y, Huang F, Fan Z, Xu Y, Sun J, et al. Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic Haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial. Lancet Oncol. 2020;21(9):1201\u201312.","journal-title":"Lancet Oncol"},{"issue":"6","key":"751_CR29","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.cell.2019.01.031","volume":"176","author":"P van Galen","year":"2019","unstructured":"van Galen P, Hovestadt V, Wadsworth Ii MH, Hughes TK, Griffin GK, Battaglia S, et al. Single-Cell RNA-Seq reveals AML hierarchies relevant to disease progression and immunity. Cell. 2019;176(6):1265\u2013e8124.","journal-title":"Cell"},{"issue":"11","key":"751_CR30","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1038\/nmeth.4463","volume":"14","author":"S Aibar","year":"2017","unstructured":"Aibar S, Gonz\u00e1lez-Blas CB, Moerman T, Huynh-Thu VA, Imrichova H, Hulselmans G, et al. SCENIC: single-cell regulatory network inference and clustering. Nat Methods. 2017;14(11):1083\u20136.","journal-title":"Nat Methods"},{"issue":"6","key":"751_CR31","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1038\/s41591-022-01819-x","volume":"28","author":"AGX Zeng","year":"2022","unstructured":"Zeng AGX, Bansal S, Jin L, Mitchell A, Chen WC, Abbas HA, et al. A cellular hierarchy framework for Understanding heterogeneity and predicting drug response in acute myeloid leukemia. Nat Med. 2022;28(6):1212\u201323.","journal-title":"Nat Med"},{"issue":"Suppl 19","key":"751_CR32","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1186\/s12859-019-3211-9","volume":"20","author":"Y Cao","year":"2019","unstructured":"Cao Y, Lin Y, Ormerod JT, Yang P, Yang JYH, Lo KK. ScDC: single cell differential composition analysis. BMC Bioinformatics. 2019;20(Suppl 19):721.","journal-title":"BMC Bioinformatics"},{"issue":"7633","key":"751_CR33","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SWK Ng","year":"2016","unstructured":"Ng SWK, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, et al. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433\u20137.","journal-title":"Nature"},{"issue":"1","key":"751_CR34","doi-asserted-by":"publisher","first-page":"7955","DOI":"10.1038\/s41467-025-63271-y","volume":"16","author":"T Mikami","year":"2025","unstructured":"Mikami T, Kato I, Nishimura A, Eguchi-Ishimae M, Kamitori T, Tasaka K, et al. Multi-omics analysis identifies an M-MDSC-like immunosuppressive phenotype in lineage-switched AML with KMT2A rearrangement. Nat Commun. 2025;16(1):7955.","journal-title":"Nat Commun"},{"issue":"7728","key":"751_CR35","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1038\/s41586-018-0623-z","volume":"562","author":"JW Tyner","year":"2018","unstructured":"Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. 2018;562(7728):526\u201331.","journal-title":"Nature"},{"issue":"8","key":"751_CR36","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40(8):850\u2013e649.","journal-title":"Cancer Cell"},{"issue":"22","key":"751_CR37","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","volume":"368","author":"TJ Ley","year":"2013","unstructured":"Ley TJ, Miller C, Ding L, Raphael BJ, Mungall AJ, Robertson AG, et al. Genomic and epigenomic landscapes of adult de Novo acute myeloid leukemia. N Engl J Med. 2013;368(22):2059\u201374.","journal-title":"N Engl J Med"},{"issue":"1","key":"751_CR38","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2024","unstructured":"Jin S, Plikus MV, Nie Q. CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics. Nat Protoc. 2024;20(1):180\u2013219.","journal-title":"Nat Protoc"},{"issue":"7965","key":"751_CR39","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41586-023-06130-4","volume":"618","author":"A Gavish","year":"2023","unstructured":"Gavish A, Tyler M, Greenwald AC, Hoefflin R, Simkin D, Tschernichovsky R, et al. Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours. Nature. 2023;618(7965):598\u2013606.","journal-title":"Nature"},{"issue":"4","key":"751_CR40","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1038\/s41375-024-02137-6","volume":"38","author":"JF Severens","year":"2024","unstructured":"Severens JF, Karakaslar EO, van der Reijden BA, S\u00e1nchez-L\u00f3pez E, van den Berg RR, Halkes CJM, et al. Mapping AML heterogeneity - multi-cohort transcriptomic analysis identifies novel clusters and divergent ex-vivo drug responses. Leukemia. 2024;38(4):751\u201361.","journal-title":"Leukemia"},{"issue":"8","key":"751_CR41","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-15-1015","volume":"76","author":"JE Farrar","year":"2016","unstructured":"Farrar JE, Schuback HL, Ries RE, Wai D, Hampton OA, Trevino LR, et al. Genomic profiling of pediatric acute myeloid leukemia reveals a changing mutational landscape from disease diagnosis to relapse. Cancer Res. 2016;76(8):2197\u2013205.","journal-title":"Cancer Res"},{"issue":"16","key":"751_CR42","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1182\/blood-2015-11-683649","volume":"127","author":"C Pabst","year":"2016","unstructured":"Pabst C, Bergeron A, Lavall\u00e9e VP, Yeh J, Gendron P, Norddahl GL, et al. GPR56 identifies primary human acute myeloid leukemia cells with high repopulating potential in vivo. Blood. 2016;127(16):2018\u201327.","journal-title":"Blood"},{"issue":"9","key":"751_CR43","doi-asserted-by":"publisher","first-page":"e72884","DOI":"10.1371\/journal.pone.0072884","volume":"8","author":"T Macrae","year":"2013","unstructured":"Macrae T, Sargeant T, Lemieux S, H\u00e9bert J, Deneault E, Sauvageau G. RNA-Seq reveals spliceosome and proteasome genes as most consistent transcripts in human cancer cells. PLoS ONE. 2013;8(9):e72884.","journal-title":"PLoS ONE"},{"issue":"20","key":"751_CR44","doi-asserted-by":"publisher","first-page":"2498","DOI":"10.1182\/blood-2016-03-703868","volume":"127","author":"VP Lavall\u00e9e","year":"2016","unstructured":"Lavall\u00e9e VP, Lemieux S, Boucher G, Gendron P, Boivin I, Armstrong RN, et al. RNA-sequencing analysis of core binding factor AML identifies recurrent ZBTB7A mutations and defines RUNX1-CBFA2T3 fusion signature. Blood. 2016;127(20):2498\u2013501.","journal-title":"Blood"},{"issue":"9","key":"751_CR45","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/ng.3371","volume":"47","author":"VP Lavall\u00e9e","year":"2015","unstructured":"Lavall\u00e9e VP, Baccelli I, Krosl J, Wilhelm B, Barab\u00e9 F, Gendron P, et al. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias. Nat Genet. 2015;47(9):1030\u20137.","journal-title":"Nat Genet"},{"issue":"1","key":"751_CR46","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41375-020-0762-8","volume":"35","author":"W Arindrarto","year":"2021","unstructured":"Arindrarto W, Borr\u00e0s DM, de Groen RAL, van den Berg RR, Locher IJ, van Diessen S, et al. Comprehensive diagnostics of acute myeloid leukemia by whole transcriptome RNA sequencing. Leukemia. 2021;35(1):47\u201361.","journal-title":"Leukemia"},{"issue":"13","key":"751_CR47","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1182\/blood-2016-07-730614","volume":"129","author":"AR Pyzer","year":"2017","unstructured":"Pyzer AR, Stroopinsky D, Rajabi H, Washington A, Tagde A, Coll M, et al. MUC1-mediated induction of myeloid-derived suppressor cells in patients with acute myeloid leukemia. Blood. 2017;129(13):1791\u2013801.","journal-title":"Blood"},{"issue":"1","key":"751_CR48","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s40164-024-00514-6","volume":"13","author":"T Hu","year":"2024","unstructured":"Hu T, Cheng B, Matsunaga A, Zhang T, Lu X, Fang H, et al. Single-cell analysis defines highly specific leukemia-induced neutrophils and links MMP8 expression to recruitment of tumor associated neutrophils during FGFR1 driven leukemogenesis. Experimental Hematol Oncol. 2024;13(1):49.","journal-title":"Experimental Hematol Oncol"},{"issue":"1","key":"751_CR49","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1186\/s13287-025-04525-w","volume":"16","author":"J Qi","year":"2025","unstructured":"Qi J, Zhao X, Gao X, Zhu X, Wang J, Liu J, et al. Overexpression of SOX4 in MSCs inhibits cellular senescence and enhances therapeutic efficacy in systemic lupus erythematosus. Stem Cell Res Ther. 2025;16(1):380.","journal-title":"Stem Cell Res Ther"},{"issue":"10","key":"751_CR50","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-020-1008-z","volume":"26","author":"E Bernard","year":"2020","unstructured":"Bernard E, Nannya Y, Hasserjian RP, Devlin SM, Tuechler H, Medina-Martinez JS, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549\u201356.","journal-title":"Nat Med"},{"issue":"20","key":"751_CR51","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1182\/bloodadvances.2020002512","volume":"4","author":"J Vadakekolathu","year":"2020","unstructured":"Vadakekolathu J, Lai C, Reeder S, Church SE, Hood T, Lourdusamy A, et al. TP53 abnormalities correlate with immune infiltration and associate with response to Flotetuzumab immunotherapy in AML. Blood Adv. 2020;4(20):5011\u201324.","journal-title":"Blood Adv"},{"issue":"1","key":"751_CR52","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/s41375-024-02415-3","volume":"39","author":"C Goda","year":"2025","unstructured":"Goda C, Kulkarni R, Bustos Y, Li W, Rudich A, Balcioglu O, et al. Cellular taxonomy of the preleukemic bone marrow niche of acute myeloid leukemia. Leukemia. 2025;39(1):51\u201363.","journal-title":"Leukemia"},{"issue":"8075","key":"751_CR53","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41586-025-09018-7","volume":"644","author":"S Sharma","year":"2025","unstructured":"Sharma S, Rodems BJ, Baker CD, Kaszuba CM, Franco EI, Smith BR, et al. Taurine from tumour niche drives Glycolysis to promote leukaemogenesis. Nature. 2025;644(8075):263\u201372.","journal-title":"Nature"},{"issue":"5","key":"751_CR54","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","volume":"54","author":"S Hegde","year":"2021","unstructured":"Hegde S, Leader AM, Merad M. MDSC: Markers, development, states, and unaddressed complexity. Immunity. 2021;54(5):875\u201384.","journal-title":"Immunity"},{"issue":"1","key":"751_CR55","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13045-025-01731-0","volume":"18","author":"Y Feng","year":"2025","unstructured":"Feng Y, Liu G, Li H, Cheng L. Target neutrophil heterogeneity and plasticity in cancer. J Hematol Oncol. 2025;18(1):79.","journal-title":"J Hematol Oncol"},{"issue":"12","key":"751_CR56","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/j.ccell.2022.10.008","volume":"40","author":"S Salcher","year":"2022","unstructured":"Salcher S, Sturm G, Horvath L, Untergasser G, Kuempers C, Fotakis G, et al. High-resolution single-cell atlas reveals diversity and plasticity of tissue-resident neutrophils in non-small cell lung cancer. Cancer Cell. 2022;40(12):1503.","journal-title":"Cancer Cell"},{"issue":"1","key":"751_CR57","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1186\/s13045-024-01566-1","volume":"17","author":"D Chai","year":"2024","unstructured":"Chai D, Wang J, Fan C, Lim JM, Wang X, Neeli P, et al. Remodeling of anti-tumor immunity with antibodies targeting a p53 mutant. J Hematol Oncol. 2024;17(1):45.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"751_CR58","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-024-01567-0","volume":"17","author":"S Naik","year":"2024","unstructured":"Naik S, Li Y, Talleur AC, Selukar S, Ashcraft E, Cheng C, et al. Memory T-cell enriched haploidentical transplantation with NK cell addback results in promising long-term outcomes: a phase II trial. J Hematol Oncol. 2024;17(1):50.","journal-title":"J Hematol Oncol"},{"issue":"2","key":"751_CR59","doi-asserted-by":"publisher","first-page":"403","DOI":"10.3324\/haematol.2020.259531","volume":"107","author":"R Birsen","year":"2022","unstructured":"Birsen R, Larrue C, Decroocq J, Johnson N, Guiraud N, Gotanegre M, et al. APR-246 induces early cell death by ferroptosis in acute myeloid leukemia. Haematologica. 2022;107(2):403\u201316.","journal-title":"Haematologica"},{"issue":"7","key":"751_CR60","doi-asserted-by":"publisher","first-page":"e70164","DOI":"10.1002\/hem3.70164","volume":"9","author":"DA Sallman","year":"2025","unstructured":"Sallman DA, Komrokji RS, Dezern AE, Sebert M, Garcia-Manero G, Rahm\u00e9 R, et al. Long-term follow-up and combined phase 2 results of Eprenetapopt and Azacitidine in patients with TP53 mutant MDS\/AML. HemaSphere. 2025;9(7):e70164.","journal-title":"HemaSphere"},{"issue":"21","key":"751_CR61","doi-asserted-by":"publisher","first-page":"6492","DOI":"10.1182\/bloodadvances.2023010956","volume":"7","author":"F Ravandi","year":"2023","unstructured":"Ravandi F, Bashey A, Foran J, Stock W, Mawad R, Short N, et al. Phase 1 study of Vibecotamab identifies an optimized dose for treatment of relapsed\/refractory acute myeloid leukemia. Blood Adv. 2023;7(21):6492\u2013505.","journal-title":"Blood Adv"}],"container-title":["Experimental Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40164-026-00751-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40164-026-00751-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,5]],"date-time":"2026-02-05T20:02:55Z","timestamp":1770321775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s40164-026-00751-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,3]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["751"],"URL":"https:\/\/doi.org\/10.1186\/s40164-026-00751-x","relation":{},"ISSN":["2162-3619"],"issn-type":[{"value":"2162-3619","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,3]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the Ethics Committee of Nanfang Hospital, Southern Medical University (Guangzhou, China). Written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors have reviewed and approved the submission and publication of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}